Study of GS-4528 in Adults With Solid Tumors
Running, not enrolling · Phase 1
Conditions studied: Solid Tumor
In brief
The goals of this clinical study are to identify if GS-4528 alone or in combination with anti-programmed cell death protein 1 (PD-1) (Anti-PD-1) Monoclonal Antibody is safe and tolerable in people with solid tumors and to identify the recommended dose of GS-4528 for further development that is safe to give to people alone or in combination with Anti-PD-1 Monoclonal Antibody. The primary objectives of this study are: * To assess the safety and tolerability of GS-4528 as monotherapy and in combination with Anti-PD-1 Monoclonal Antibody in participants with advanced solid tumors. * To identify the maximum tolerated dose (MTD)/maximum administered dose (MAD) and/or the recommended Phase 2 dose (RP2D) of GS-4528 as monotherapy and in combination with Anti-PD-1 Monoclonal Antibody in participants with advanced solid tumors.
Key facts
- Study ID
- NCT05840224
- Run by
- Gilead Sciences
- People needed
- 182
- Starts
- 2023-05-11
- Expected to finish
- 2026-10-01
- Last updated by the study team
- 2026-07-27
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- The University of Washington/FHCC — Seattle, Washington, United States
- The Ottawa Hospital — Ottawa, Canada
- University Health Network, Princess Margaret Cancer Centre — Toronto, Canada
- Asan Medical Center — Seoul, South Korea
- Severance Hospital, Yonsei University Health Systems — Seoul, South Korea
- Samsung Medical Center — Seoul, South Korea
- NEXT Oncology-Hospital Quironsalud Barcelona - Unidad de Ensayos Fase 1 — Barcelona, Spain
- Hospital Universitari Vall D'Hebron- Oncology Service — Barcelona, Spain
- START MADRID_Hospital Universitario Fundacion Jimenez Diaz - Unidad de Ensayos Fases I — Madrid, Spain
- START MADRID_HM Sanchinarro-CIOCC-Unidad de Ensayos Fases I — Madrid, Spain
- Clinica Universidad de Navarra- Unidad Central de Ensayos Clinicos — Pamplona, Spain
- Taichung Veterans General Hospital — Taichung, Taiwan
- National Taiwan University Hospital — Taipei, Taiwan
- Chang Gung Memorial Hospital Linkuo Branch of the Chang Gung Medical Foundation — Taoyuan, Taiwan
- St Bartholomew's Hospital — London, United Kingdom
- The Royal Marsden NHS Foundation Trust — Sutton, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.